Sherwin-Williams’ Duckback and SuperDeck Coating Products False Advertising Class Action Investigation

Magellan All LeadCare Blood Lead Testing Systems Healthcare Provider Investigation

Chimicles & Tikellis is investigating a potential class action lawsuit on behalf of hospitals, healthcare providers and doctors that paid for a blood lead testing system sold by Magellan Diagnostics Inc. (a subsidiary of Meridian Bioscience).

Magellan All LeadCare Blood Lead Testing Systems Patient Investigation

Chimicles & Tikellis is investigating a potential class action lawsuit on behalf of patients and third party payors against Meridian Bioscience related to a blood lead testing system sold by its subsidiary, Magellan Diagnostics Inc. The Food and Drug Administration issued a Safety Notice on May 17, 2017 “warning Americans that certain lead tests manufactured by Magellan Diagnostics may provide inaccurate results for some children and adults in the United States” and recommending that parents of young children, pregnant women and nursing mothers who have been tested for lead exposure with this device “consult a health care professional about whether they should be retested.”

Behr’s DeckOver False Advertising Class Action Investigation

Chimicles & Tikellis LLP is investigating a potential class action lawsuit related to the alleged false advertising of Behr’s DeckOver product. Sold exclusively at Home Depot, DeckOver is advertised as offering resilient protection for wood and concrete surfaces.

Electrolux and Frigidaire Refrigerator Fire Class Action Investigation

Chimicles & Tikellis is investigating a potential class action against Electrolux relating to a safety defect causing certain models of Frigidaire or Electrolux refrigerators to catch fire.

Health Insurer and Pharmacy Benefit Manager Unlawful Retention of Prescription Drug Rebates – Class Action Investigation

Insurance Industry Unlawful Prescription Drug Co-Payment Clawback Scheme – Class Action Investigation

Chimicles & Tikellis LLP (“C&T”) is investigating reports of an alleged scheme whereby insurance companies may charge insureds a “co-payment” for a prescription drug that far exceeds the actual cost of the drug to the insurance company.